18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT).

[1]  K Kubota,et al.  Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  S. P. Reddy,et al.  Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation. , 1997, International journal of radiation oncology, biology, physics.

[3]  A. Buck,et al.  Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[5]  M Schwaiger,et al.  Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  B. Glimelius,et al.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  L. Mortelmans,et al.  Clinical value of whole‐body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer , 1994, The British journal of surgery.

[8]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  G. Daugaard.  Unknown primary tumours. , 1994, Cancer treatment reviews.

[10]  R L Wahl,et al.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.

[11]  R. Wahl,et al.  Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[13]  J. Hainsworth,et al.  Treatment of patients with cancer of an unknown primary site. , 1993, The New England journal of medicine.

[14]  Michael E. Phelps,et al.  Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose , 1993, Journal of computer assisted tomography.

[15]  E. Rota Kops,et al.  The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[17]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  M. Salvatore,et al.  High serum thyroglobulin levels: Diagnostic indicators in patients with metastases from unknown primary sites , 1987, Cancer.

[19]  P. Sheedy,et al.  Computed tomography in search of cancer of unknown origin. , 1982, JAMA.

[20]  E. Levine,et al.  Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study. , 1982, Radiology.

[21]  J S Fowler,et al.  A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  M. Viola,et al.  Identifying the primary site in metastatic cancer of unknown origin. Inadequacy of roentgenographic procedures. , 1979, JAMA.

[23]  R. M. Wolf,et al.  Metastatic and histologic presentations in unknown primary cancer. , 1977, Seminars in oncology.

[24]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[25]  W Cramer,et al.  On the Origin of Cancer* , 1938, British medical journal.

[26]  M. Ranson,et al.  Chemotherapy in non-small cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  U Ruotsalainen,et al.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.